MELI: Optimistic Fair Value Target Collides with Near-Term Margin Risks

What happened

MercadoLibre (MELI) has fallen over 35% from its 2025 peak, and a recent Seeking Alpha article argues the sell-off is overdone, citing 49% revenue growth and a sustainable net margin of 6.5%-7.0% that supports a fair value of $2,030–$2,185 per share. However, the DeepValue report assigns a WAIT rating with a base case of $1,750, emphasizing that Q1'26 operating income dropped 20% year-over-year to $611 million as gross margin compressed to 43.7% (from 46.7%) due to reduced free-shipping thresholds in Brazil and higher shipping costs. Meanwhile, credit provisioning surged to $1.24 billion (from $603 million), and NIMAL fell to 17.8% (from 22.7%), signaling that the credit engine is becoming less profitable. Although funding flexibility through receivables sales ($367 million in gains) and an undrawn $800 million revolver provides a cushion, the core issue is that structural margin pressure from logistics and credit has not yet stabilized. The stock at ~$1,660 (P/E 44x, EV/EBITDA 20x) prices in a return to margin expansion that requires concrete proof in Q2'26—not just narrative comfort.

Implication

Investors should remain on the sidelines for the next 3-6 months. The DeepValue report's WAIT rating reflects a need for evidence that shipping costs and credit provisions are peaking. If Q2'26 shows gross margin flat-to-up and NIMAL at or above 17.8%, the path to the bull case ($2,050) becomes credible. Conversely, further margin compression and rising provisions would validate the bear case ($1,250). The Seeking Alpha article's fair value target may prove correct over 12+ months, but near-term catalysts are absent; the best risk/reward is to wait for stabilization signals before committing capital.

Thesis delta

The Seeking Alpha article frames the 35% decline as a buying opportunity with 20-29% upside based on normalized margins. The DeepValue report, however, insists the investment thesis has not yet been proven: the core assumption—that gross margin and NIMAL will stabilize—is still untested. Until Q2'26 evidence emerges, the thesis remains 'show me,' not 'buy the dip.' The delta is that the article's long-term fair value is plausible only if the near-term margin deterioration reverses, which is far from certain.